Resources for Genetics Professionals — Genetic Disorders Associated with Founder Variants Common in the Gitxsan Population
Stephanie E Wallace, MD
Senior Editor, GeneReviews
Clinical Professor, Department of Pediatrics
University of Washington
Seattle, Washington
Madelyn A Gillentine, PhD
Consulting Editor, GeneReviews
Variant Scientist, Department of Laboratories
Seattle Children’s Hospital
Seattle, Washington
Initial Posting: August 11, 2022.
Estimated reading time: 1 minute
A founder variant is a pathogenic variant observed at high frequency in a specific population due to the presence of the variant in a single ancestor or small number of ancestors. The presence of a founder variant can affect the approach to molecular genetic testing. When one or more founder variants account for a large percentage of all pathogenic variants found in a population, testing for the founder variant(s) may be performed first.
The table below includes common founder variants – here defined as three or fewer variants that account for >50% of the pathogenic variants identified in a single gene in individuals of a specific ancestry – in individuals of Gitxsan ancestry. Note: Pathogenic variants that are common worldwide due to a DNA sequence hot spot are not considered founder variants and thus are not included.
Table.
Genetic Disorders Associated with Founder Variants Common in the Gitxsan Population
View in own window
Included if ≤3 pathogenic variants account for ≥50% of variants identified in a specific ethnic group
AD = autosomal dominant; MOI = mode of inheritance; NA = not applicable
- 1.
This percentage does not account for the possibility of rare de novo pathogenic variants occurring in this population.
References
Arbour L, Rezazadeh S, Eldstrom J, Weget-Simms G, Rupps R, Dyer Z, Tibbits G, Accili E, Casey B, Kmetic A, Sanatani S, Fedida D. A. KCNQ1 V205M missense mutation causes a high rate of long QT syndrome in a First Nations community of northern British Columbia: a community-based approach to understanding the impact.
Genet Med. 2008;10:545–50. [
PubMed: 18580685]
Jackson HA, McIntosh S, Whittome B, Asuri S, Casey B, Kerr C, Tang A, Arbour LT. LQTS in northern BC: homozygosity for KCNQ1 V205M presents with a more severe cardiac phenotype but with minimal impact on auditory function.
Clin Genet. 2014;86:85–90. [
PubMed: 23844633]
Swayne LA, Murphy NP, Asuri S, Chen L, Xu X, McIntosh S, Wang C, Lancione PJ, Roberts JD, Kerr C, Sanatani S, Sherwin E, Kline CF, Zhang M, Mohler PJ, Arbour LT. Novel variant in the
ANK2 membrane-binding domain is associated with ankyrin-B syndrome and structural heart disease in a First Nations population with a high rate of long QT syndrome.
Circ Cardiovasc Genet. 2017;10:e001537. [
PMC free article: PMC5312931] [
PubMed: 28196901]